Published in Pharma Law Weekly, March 21st, 2006
Within the frame of this contract, ProBioGen will develop a high-producing cell-line as well as a production process and procedure with GMP-manufacturing for clinical material for a TandAB, a bi-specific, tetravalent recombinant antibody, from Affimed.
Meanwhile, both companies are discussing extending their collaboration to other products. The cooperation between ProBioGen and Affimed reached a new level of intensity with this contract. "We...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly